Vol 9, No 3 (2007)
REVIEWS AND LECTURES
ORIGINAL ARTICLES
224-227 4
Abstract
Recent developments in hemodialysis techniques have spurred new interest in the field of the permanent vascular access for HD. The program of creating and maintaining a reliable vascular access in hemodialysis patients is today seen as a multidisciplinary task that must include the collaboration of nephrologists, surgeons and hemodialysis specialists. Earlier cannulation of a newly placed permanent vascular access at the haemodialysis facility level may be associated with increased risk of vascular access failure. The aim of this article is to review different etiologies of impaired fistula maturation in order to improve the rate of fistula maturation and increase the number of dialysis patients with a functioning autogenous fistula.
E. T. Egorova,
N. A. Tomilina,
L. S. Birukova,
A. V. Sukhanov,
E. S. Stoliarevich,
O. A. Kupavtseva,
N. D. Fedorova,
L. G. Kurenkova
228-239 3
Abstract
19 patients (12 men, 7 women) with ANCA-associated vasculitis and with morphological pictures of pauciimmune rapidly progressive glomerulonephritis were analyzed retrospectively. All patients received immunosuppressive therapy including a combination of cyclofosfamide and prednisolone (intravenous and oral). In 15 of 19 patients the therapy was successful as judged from a decrease in serum creatinine level from 790 (400; 1025) to 200 (120; 320) µmol/l and in proteinuria level from 0,9 (0,5; 2,2) to 0,16 (0,06; 0,8) g/day. Renal recovery in pauciimmune rapidly progressive glomerulonephritis did not depend on clinical manifestations of ANCA-associated vasculitis, level of renal insufficiency or extracapillary proliferation. The main predictor of patient’s response to the therapy was severity of glomerulosclerosis. In this case only a partial remission of renal disease could be achieved.
EDUCATIONAL MATERIALS
240-247 11
Abstract
Pregnancy in women with chronic kidney disease is mostly successful when kidney function is well and hypertension is absent. Counseling and managing women with chronic renal diseases is based on the following general approach: fertility and ability to sustain an uncomplicated pregnancy relate to the degree of functional impairment, and whether hypertension is present, and not to underlying disorder. Only in some diseases, such as sclerodermia, poliarteriitis nodosa, lupus flare and definite forms of chronic glomerulonephritis, underlying disorder play the main role, as well as renal failure and malignant hypertension.
M. . Auerbach,
J. . Winchester,
A. . Wahab,
K. . Richards,
M. . Mcginley,
F. . Hall,
J. . Anderson,
G. . Briefel
247-252 7
Abstract
Forty-three hemodialysis patients receiving recombinant erythropoietin (rHuEPO, epoietin alpha) were randomized to receive intravenous iron dextran as a total-dose infusion, 500 mg infusion to total dose, or 100 mg bolus to total dose, in each case during the dialysis procedure. The dose of iron dextran was calculated from the patient’s existing hemoglobin to achieve a desired hemoglobin. Patients were eligible to receive intravenous iron dextran if they had a serum ferritin less than 100 ng/ml or a serum ferritin of 100 to 200 ng/ml, along with a transferrin saturation of ≤19%. Patients were excluded if they had prior therapy with iron dextran, aluminum intoxication, or transfusion during the study. The time to the maximum hemoglobin, acute adverse reactions, and delayed adverse reactions were analyzed statistically, and no differences were seen in any of the three groups. Total-dose intravenous iron dextran infusion is safe, convenient, less expensive, and as efficacious as divided-dose infusions.
IN MEMORIAM
V КОНФЕРЕНЦИЯ РДО (19-21 СЕНТЯБРЯ 2007 Г.) А. ЭКСПЕРИМЕНТАЛЬНАЯ И КЛИНИЧЕСКАЯ ПАТОФИЗИОЛОГИЯ, ЭКСПЕРИМЕНТАЛЬНАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ ПОЧЕК И РАССТРОЙСТВ ВОДНО-СОЛЕВОГО ОБМЕНА
V КОНФЕРЕНЦИЯ РДО (19-21 СЕНТЯБРЯ 2007 Г.) Б. ПРОБЛЕМЫ ХПН Б.1. ОБЩИЕ ВОПРОСЫ
V КОНФЕРЕНЦИЯ РДО (19-21 СЕНТЯБРЯ 2007 Г.) Б. ПРОБЛЕМЫ ХПН Б.2. КАРДИО-ВАСКУЛЯРНАЯ ПАТОЛОГИЯ
V КОНФЕРЕНЦИЯ РДО (19-21 СЕНТЯБРЯ 2007 Г.) В. ЗАМЕСТИТЕЛЬНАЯ ТЕРАПИЯ ТЕРМИНАЛЬНОЙ ХПН В.1. ОБЩИЕ ВОПРОСЫ
V КОНФЕРЕНЦИЯ РДО (19-21 СЕНТЯБРЯ 2007 Г.) В. ЗАМЕСТИТЕЛЬНАЯ ТЕРАПИЯ ТЕРМИНАЛЬНОЙ ХПН. В.2. ПРОГРАММНЫЙ ГЕМОДИАЛИЗ
V КОНФЕРЕНЦИЯ РДО (19-21 СЕНТЯБРЯ 2007 Г.) В. ЗАМЕСТИТЕЛЬНАЯ ТЕРАПИЯ ТЕРМИНАЛЬНОЙ ХПН. В.3. ПОСТОЯННЫЙ АМБУЛАТОРНЫЙ ПЕРИТОНЕАЛЬНЫЙ ДИАЛИЗ
V КОНФЕРЕНЦИЯ РДО (19-21 СЕНТЯБРЯ 2007 Г.) В. ЗАМЕСТИТЕЛЬНАЯ ТЕРАПИЯ ТЕРМИНАЛЬНОЙ ХПН. В.4. ТРАНСПЛАНТАЦИЯ ПОЧКИ
V КОНФЕРЕНЦИЯ РДО (19-21 СЕНТЯБРЯ 2007 Г.) Г. ОСТРАЯ ПОЧЕЧНАЯ НЕДОСТАТОЧНОСТЬ
V КОНФЕРЕНЦИЯ РДО (19-21 СЕНТЯБРЯ 2007 Г.) Д. ПРОБЛЕМЫ КЛИНИЧЕСКОЙ НЕФРОЛОГИИ
V КОНФЕРЕНЦИЯ РДО (19-21 СЕНТЯБРЯ 2007 Г.) Е. ВОПРОСЫ ДЕТСКОЙ НЕФРОЛОГИИ
ISSN 1680-4422 (Print)
ISSN 2618-9801 (Online)
ISSN 2618-9801 (Online)
